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animals (9). The consequence of this delayed protective immune response is the inability to clear off the PRRSV from the
tissues during the acute periods of infection when most of
tissue damage, abundant viral replication, excretion, and contact transmission take place. It has been recently proposed that
the ensuing persistence of PRRSV in infected animals would
represent the inability of adaptive immunity to overcome the
ongoing infection (21). These authors assign instead a more
pivotal role in such a process to the combined effect of innate
immunity and the mere fluctuation or depletion in the number
of subpopulations of macrophages permissive to PRRSV infection that are available in vivo (21), as had been previously
proposed for the murine arterivirus LDV (15). The actual
disappearance of the persistent PRRSV from tissues of individual animals does not take place until much later in the
infection process, at postinfection times well beyond the actual
appearance of NA or gamma interferon-producing cells to
permit any correlation of these immune factors’ appearance
with viral clearance (2).
Although it is clear that the adaptive immune effectors are
unable to mediate rapid viral clearance during natural PRRSV
infection, strong evidence exists indicating that some of these
same immune parameters may provide solid protective immunity
when present in the body at the time of viral exposure (or evoked
shortly thereafter). A previous experiment in our laboratory has
shown that PRRSV-NA alone can fully prevent the transplacental
infection with PRRSV and extinguish the infection of PRRSV in
pregnant females (11). This observation closely correlates with
previous reports of protective vaccines or immunization regimes
inducing the appearance of PRRSV-NA which seemed to be
associated with protection (12, 14). Based on these results, NA

Porcine reproductive and respiratory syndrome causes devastating economic losses due to late-term reproductive failure
and severe pneumonia in neonatal pigs. The etiological agent
for porcine reproductive and respiratory syndrome is an RNA
virus (PRRSV), classified in the family Arteriviridae, order
Nidovirales. PRRSV consists of an enveloped, 50-nm virion,
with a single-stranded RNA⫹ genome of approximately 14.5
kb in length. Infection in late-gestation sows produces transplacental infection, leading to premature farrowing of stillborn, partially autolyzed, and mummified fetuses.
Although the establishment of PRRSV-specific convalescent
or postvaccination protective immunity is well known to occur
(5–7), the molecules or cells that mediate this protection have
not been fully identified. PRRSV-vaccinated or convalescent
animals are protected against reinfection (in a preferentially
homologous rather than heterologous PRRSV strain-specific
manner). However, it is well accepted that there is a generalized failure of the protective immune effectors to clear the
acutely replicating PRRSV in vivo, as illustrated by the late
and meager response of both PRRSV-NA and PRRSV-specific gamma interferon-producing cells in naturally infected
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Previous work in our laboratory demonstrated that passive transfer of porcine reproductive and respiratory
syndrome virus (PRRSV)-neutralizing antibodies (NA) protected pregnant sows against reproductive failure
and conferred sterilizing immunity in sows and offspring. We report here on the dose requirement for
protection by passive transfer with NA in young weaned pigs. The presence of a 1:8 titer of PRRSV-NA in serum
consistently protected pigs against viremia. Nevertheless, their lungs, tonsils, buffy coat cells, and peripheral
lymph nodes contained replicating PRRSV similar to the infected control group. Likewise, these animals
excreted infectious virus to sentinels similar to the infectivity control animals. In an attempt to reach complete
protective immunity equivalent to that previously observed in sows, the pigs were transferred with a higher titer
of PRRSV-NA (1:32), and even then apparent sterilizing immunity was attained in only 50% of the animals. In
conclusion, the presence of anti-PRRSV-NA in serum with a titer of 1:8 is enough to block viremia but not
peripheral tissue seeding and transmission to contact animals. While a relatively low level of NA in blood is
capable of conferring sterilizing immunity against PRRSV in sows, the amount of NA necessary to obtain full
protection of a young weaned pig would be significantly higher, suggesting that differences exist in the PRRSV
pathogenesis between both age groups. In addition, the titer of NA could be a helpful parameter of protection
in the assessment of PRRSV vaccines.
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would then represent a true correlate of protective immunity
against PRRSV (11) and thus be an important parameter by
which to evaluate the efficacy of a vaccine against PRRSV. Since
the ability to induce the appearance of NA may have strong
implications for the development of efficient PRRSV vaccines, we
focused on the study of this parameter in detail. In the experiments reported here, we used a model of PRRSV challenge in
young pigs that have been passively transferred with antibodies,
which would permit us to study the optimal conditions of neutralization in vivo and the efficiency of antibodies to provide
protective immunity.
MATERIALS AND METHODS

neutralizing antibodies to the group that attained a virus-neutralizing titer of 1:32
in blood. In all cases, 1 day later, the animals were challenged with 5 ⫻ 105 50%
tissue culture infective dose(s) (TCID50) of PRRSV IA 97-7895 by the intranasal
route. PRRSV-free sentinel animals obtained from the same source were used to
determine excretion and transmission of infectious PRRSV by the principal
animals.
Viral isolation from blood and tissues. Tissue samples (lungs, bronchial lymph
nodes, tonsils, and a pool of the mesenteric, mediastinal, inguinal, and popliteal
lymph nodes) were taken at necropsy from the infected animals by using individual surgical instruments. Each tissue was cut in small pieces and homogenized,
and 1-g samples were taken to assess infectivity on MARC-145 cells as previously
described (11).
Virus neutralization assay. The titer of NA (expressed as SVN) was determined by using the fluorescence focus neutralization assay as previously described by Wu et al. (20).
ELISA. Titers of pooled sera, as well as seroconversion of the contact sentinel
animals, were determined by a commercial ELISA (Idexx PRRSV; Idexx, Portland, ME) according to the kit’s instructions.
PBMC. Blood samples were collected in heparinized tubes. Peripheral blood
mononuclear cells (PBMC) were isolated by density gradient centrifugation
using Accu-Paque lymphocytes (Accurate, Westbury, NY). Washed PBMC from
each animal were resuspended in phosphate-buffered saline and kept at ⫺80°C
until RNA extraction.
PCR for PRRSV detection. PRRSV RNA was extracted from samples as
previously described (2). RNA was subjected to reverse transcription-PCR (RTPCR) using primers capable of directing the amplification of 403- and 150-bp
fragments of ORF6 of the PRRSV IA 97-7895 strain, which was used for
challenge of the passively transferred animals. This RT-PCR assay has a sensitivity threshold for RNA detection of 103 RNA molecules (determined by an
RNA mimic). The sense and antisense primers for the outer PCR were 5⬘-AG
GTGCTCTTGGCGTTCTCTATT-3⬘ (nucleotides 14424 to 14447) and 5⬘-GCT
TTTCTGCCACCCAACACG-3⬘ (nucleotides 2848 to 2869), respectively. The
primer sequences for the nested PCR were 5⬘-CCTCCAGATGCCGTTTGTG
CT-3⬘ (nucleotides 14661 to 14682) and 5⬘-TGCCGTTGACCGTAGTGGAG
C-3⬘ (nucleotides 14790 to 14811). The cycling parameters for both PCRs were
95°C for 1 min, 60°C for 1 min, and 72°C for 1 min in a standard PCR mix with
4 mM MgCl2 for a total of 30 cycles.
Experimental design. (i) Experiment 1. To determine the minimum level of
NA protecting against viremia, six randomly selected groups of six piglets each
were intraperitoneally instilled with an immunoglobulin stock solution to attain
titers of neutralizing antibodies in serum of 1:4, 1:8, 1:16, and 1:32. The attainment of the targeted SVN in the peripheral circulation in each group of pigs was
confirmed 24 h after instillation. The SVN measured in each case was 1:4, 1:8,
1:16, and 1:32 for groups 1, 2, 3, and 4, respectively. The animals of group 5 were
intraperitoneally instilled with non-neutralizing antibodies (PRRSV-specific antibodies obtained from serum of infected pigs at 21 days postinfection, when
ELISA titers are high but no PRRSV-neutralizing activity is yet detectable). The
level of anti-PRRSV antibodies, as measured by ELISA S/P, in the latter group
was similar to the level (also measured in ELISA S/P units) attained in the group
that received NA at the 1:32 level. Group 6 did not receive antibodies. At 24 h
after immunoglobulin transfer, the six groups were challenged intranasally with
PRRSV IA 97-7895 strain. The rectal temperature was obtained daily until
euthanasia. Blood samples were collected immediately before challenge and at 4
and 7 days postinfection (p.i.). Viremia (detected on MARC-145 cells and by
RT-PCR in serum) and SVN assays were performed on these samples. At 7 days
p.i. the animals were euthanized, tissue samples were collected, and the presence
of PRRSV in tissues was detected by infectivity assay on MARC-145 cells.
(ii) Experiment 2. For the second experiment two randomly selected groups (1
and 2) of five young piglets each were intraperitoneally instilled with NA to attain
a 1:8 titer (as described previously for experiment 1) immediately prior to
intranasal challenge with 105 TCID50 PRRSV IA 97-7895 1 day later. Animals
from group 1 were euthanized at day 7 p.i., and animals from group 2 were
euthanized at day 14 p.i. A third group (n ⫽ 3) was used as an untreated, infected
control. Blood was collected before challenge and at days 4, 7, 10, and 14 p.i. and
assayed for SVN and viremia. RT-PCR was performed at day 7 p.i. in serum and
in buffy coat cells collected by Ficoll gradient centrifugation. Four sentinel
animals were used in each group as previously described (19) to determine
whether the NA-transferred animals were able to transmit PRRSV to uninfected
animals. The first two sentinel pigs were put in contact at 2 days p.i. and kept in
contact with the group for seven consecutive days. The sentinel animals were
then removed at day 9 p.i. to a clean room for an additional 21 days to verify
infection by the development of viremia or seroconversion detected by commercial ELISA Two additional sentinel pigs were added to the principal group on
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Animals. Fifteen-day-old, weaned pigs were purchased from a specific-pathogen-free herd with a certified record of absence of PRRSV infection. All animals
were tested for absence of anti-PRRSV antibodies by enzyme-linked immunosorbent assay (ELISA; Idexx Labs, Portland, ME).
Virus strains. PRRSV IA 97-7895 (1) (GenBank accession no. AF325691) was
used as previously described (11). The virus was passaged and titrated in MARC145 cells using Dulbecco modified Eagle medium supplemented with 10% fetal
bovine serum. Aliquots (1 ml) of the supernatant were stored at ⫺80°C until use.
Preparation and standardization of PRRSV-NA and non-neutralizing antibodies. The PRRSV-NA used in these experiments corresponded to the same
stock of PRRSV-NA previously used in experiments with pregnant sows (11).
These NA had been prepared by infection (PRRSV IA 97-7895), followed by
hyperimmunization of adult pigs. Serum was obtained by complete exsanguination of the hyperimmunized animals and used for extraction of immunoglobulin
G (IgG) by precipitation with ammonium sulfate as described previously (11).
For standardization of the immunoglobulin stocks, the total content of swine IgG
was determined by an antigen-capture ELISA specific for swine IgG1 and IgG2
(Bethyl Laboratories, Inc., Montgomery, TX) (11, 13). The level of potential
endotoxin contamination in the immunoglobulin solutions was determined by
using a commercially available detection kit based on Limulus amebocyte lysate
(Associates of Cape Cod, Inc., Falmouth, MA) as described previously (11).
Likewise, the possible interferon activity contained in the solution of immunoglobulins was measured by a vesicular stomatitis virus-porcine kidney cell-interferon assay (8) using genetically expressed porcine alpha interferon as a positive
control (F. A. Zuckermann, College of Veterinary Medicine, University of Illinois). In all cases, no viral interference activity was detectable. The endpoint of
PRRSV-neutralizing activity attained for the neutralizing stock solution was
1:128, which was monitored by a rapid neutralization assay of fluorescent foci on
MARC-145 cells, and was confirmed by a regular 4-day VN assay on MARC-145
cells and porcine alveolar macrophages as well. PRRSV-specific non-neutralizing
antibodies were prepared according to the same protocol of infection of adult
pigs used for the preparation of PRRSV-NA, but in this case 3 weeks after
infection the pigs were bled out by exsanguination upon testing for active seroconversion by ELISA but the absence of detectable PRRSV-neutralizing activity.
Their sera were inactivated for 30 min at 56°C, pooled, and precipitated as
described for NA. No infectious virus was detected in these pools by addition to
MARC-145 cells and also by inoculation into one PRRSV-free 15-day-old pig.
The non-neutralizing antibodies showed no neutralizing activity as monitored by
regular PRRSV VN assay. The IgG content of this non-neutralizing antibody
fraction was standardized by indirect ELISA specific for swine IgG1 and IgG2 as
described for PRRSV-NA.
Passive transfer experiments, followed by viral challenge. The immunoglobulin solutions prepared and standardized as described above were used for
passive intraperitoneal transfer into 2-week-old piglets. A pilot experiment was
performed to determine the amount of stock solution of NA (70 mg of immunoglobulin/ml) needed to reach different virus-neutralizing titers in 14-day-old
pigs, respectively, and calculations were made based on body weight, considering
a value for total blood volume as corresponding to 7% of body weight for the pig
in order to calculate the dilution factor for the instilled immunoglobulins. At 24 h
after intraperitoneal instillation and immediately before challenge, the animals
were bled, and the titer of NA in the serum of recipient piglets was evaluated by
a regular PRRSV serum virus neutralization (SVN) assay. Thus, the experiments
were performed by intraperitoneal injection of different volumes of the immunoglobulin stock solution to attain virus-neutralization titers of 1:4, 1:8, 1:16, and
1:32 in the circulation of the recipients. Animals receiving non-neutralizing
antibodies (60 to 70 mg/ml) were transferred with equivalent volumes and concentrations (determined by equivalent ELISA signal-to-positive ratios) of non-
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day 9 p.i. and kept in contact with the infected group until 14 days p.i. These
sentinel animals were removed to a clean room and maintained for an additional
21 days.
(iii) Experiment 3. In the third experiment a group of six animals received
anti-PRRSV immunoglobulins with the goal of attaining an SVN titer in serum
of at least 1:32 or more. One day later the principals plus a group of unprotected,
infected animals (n ⫽ 3) were infected with PRRSV IA 97-7895 as described for
the previous two experiments. At 7 and 14 days p.i., blood samples were collected
and viremia and SVN assays were performed. Viral isolation and RT-PCR from
tissues were performed with tissue samples at day 14 p.i. Also in this experiment,
sentinel animals were added as described above for experiment 2.
Statistical analysis. Statistical significance was determined by using the Student t test (see Fig. 2 and 3, showing the amounts of virus on tissues at 7 and 14
days p.i., respectively) and the protective least-significant-difference test (SAS
statistical program; SAS Institute, Cary, NC).

RESULTS
The minimum virus-neutralizing antibody titer in serum
that protects against viremia is 1:8. We had previously demonstrated that the passive transfer of an immunoglobulin solution
enriched for NA against PRRSV protected pregnant sows against
reproductive failure (11). Moreover, this immunoglobulin solution conferred sterilizing immunity in these sows and their offspring. The protection conferred by NA to these sows was characterized by the complete absence of viremia, which we failed to
detect, either by isolation in MARC-145 cells or by RT-PCR in
serum. Our first goal in this new series of experiments was to
determine the minimum neutralizing antibody dose for passive
protection using a young pig model. In experiment 1, 2-week-old
piglets were injected with different concentrations of PRRSVNA, which was followed 24 h later by intranasal challenge with
PRRSV. Animals receiving an amount of hyperimmune immunoglobulin sufficient to reach a PRRSV-neutralizing titer equal to
or higher than 1:8 in serum did not develop cell-free viremia after

FIG. 2. Correlation between the titer of NA and the viral load in
bronchial lymph nodes and lungs. Fifteen-day-old pigs were passively
transferred with either neutralizing immunoglobulins to attain titers of
1:4, 1:8, 1:16, and 1:32, non-neutralizing antibodies (NNA), or no antibodies (Ctrl) and challenged with PRRSV 1 day later (experiment 1). The
virus titers in the bronchial lymph nodes (o) and lungs (■) at day 7 p.i. are
shown. Columns with different letters are marginally significantly different
in the lymph nodes (P ⫽ 0.06) and significantly different in the lung (P ⬍
0.05 by Student t test, 11 df). Ctrl, animals were not transferred with
antibodies; NNA, animals were transferred with non-NA. Groups 1:4, 1:8,
1:16, and 1:32 indicate the different groups of animals that, when passively
transferred with different quantities of NA, attained peripheral SVN titers
of 1:4, 1:8, 1:16, and 1:32, respectively.

viral challenge (Fig. 1). The absence of virus in serum was confirmed by RT-PCR (data not shown). On the other hand, animals
with a titer of 1:4 at the time of challenge developed viremia.
Virus titers in blood of the latter animals, however, were lower
(P ⬍ 0.05, Student t test) than those in the infected controls.
Moreover, three of three animals from this group did not show
virus in blood 4 days p.i., indicating that the presence of some
level of NA in blood can block viremia for at least a short time p.i.
In addition, a group of animals receiving an equivalent dose of
non-PRRSV-NA (i.e., immunoglobulins collected from PRRSVinfected animals within the first 3 weeks p.i.) showed titers of virus
in blood similar to those seen in unprotected, infected controls,
indicating that these immunoglobulin solutions containing the
early appearing, non-PRRSV-NA were not protective against
experimental challenge with PRRSV (Fig. 1).
The body temperature of the different groups in experiment
1, except for group 5, did not rise significantly during the 7 days
of observation except for the last day of observation (day
7 p.i.), when a slight increase in the body temperature was
observed in the groups 1, 2, and 6 (1:4, 1:8, and the “no
antibodies” group). Group 5, receiving non-neutralizing antibody solutions, became hyperthermic between days 1 and 7 p.i.
(data not shown).
A titer of PRRSV-NA of 1:8 does not protect against replication of PRRSV in the primary site of viral replication and
draining lymph nodes of challenged pigs. Even though no virus
was detected in the sera of animals exhibiting a titer equal to
or higher than 1: 8 (Fig. 1), PRRSV was detected in the lungs
and draining bronchial lymph node of these animals when
necropsied at day 7 p.i. (Fig. 2). It should be noted, however,
that the amount of virus was significantly lower in lungs (P ⬍
0.05 by Student t test) and marginally significant in bronchial
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FIG. 1. Correlation between titer of NA and virus in serum detected by viral isolation. Two-week-old pigs were passively transferred
with different amounts of a stock of immunoglobulin with NA that
attained a range of SVN titers (1:32, 1:16, 1:8, and 1:4). One group
received non-neutralizing antibodies (NNA), and another group did
not receive antibodies at all (Ctrl). One day later, animals were intranasally challenged with 5 ⫻ 105 TCID50 of PRRSV, and the virus levels
in serum were determined by viral isolation from MARC-145 cells and
RT-PCR (the RT-PCR data is not shown in figure but is mentioned in
the text) at days 4 and 7 p.i. as indicated in Materials and Methods.
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TABLE 1. Association between titer of NA in blood and absence of viremia after challengea
SVN atb:
Day 7 p.i.

61
63
64
66
73
44
45
46
47
48
67
68
70
71
74

1:8
1:8
1:8
1:8
1:8
1:8
1:8
1:8
1:8
1:8
Neg
Neg
Neg
Neg
Neg

1:4
1:4
1:8
1:4
1:2
1:8
1:4
1:4
1:8
1:8
Neg
Neg
Neg
Neg
Neg

Neg
Neg
Neg
Neg
102.6
Neg
Neg
Neg
Neg
Neg
105.2
104.0
103.5
103.6
104.6

RT-PCR resultd

SVN
at day
14 p.i.b

Viremia
at day
14 p.i.c

Serum

Buffy coat

Time necropsy
was conducted
(days p.i.)

N/A
N/A
N/A
N/A
N/A
1:4
1:4
1:2
1:4
1:4
Neg
Neg
Neg
Neg
Neg

N/A
N/A
N/A
N/A
N/A
103.0
Neg
102.6
Neg
Neg
ND
ND
ND
ND
ND

Neg
Neg
Neg
Neg
Pos
Pos
ND
Pos
ND
ND
Pos
Pos
Pos
Pos
Pos

Neg
Pos
Pos
Pos
Pos
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

7
7
7
7
7
14
14
14
14
14
14
14
14
14
14

a
A group of 15-day-old pigs (n ⫽ 10) were transferred with NA to reach an SVN titer of 1:8 and subsequently challenged with PRRSV. A control group (n ⫽ 5)
did not receive antibodies and was infected with PRRSV.
b
Titer of PRRSV-NA transferred by passive transfer. The titer of NA (SVN) was determined at days 7 and 14 p.i. Neg, negative; N/A, not applicable.
c
Viremia was determined at days 7 and 14 p.i. Values are TCID50/ml of serum. Neg, infectivity was below the threshold of detection (⬍10 TCID50/ml).
d
RT-PCR was performed in PBMC in the animals necropsied at day 7 p.i. and in serum in the other necropsied animals.

lymph nodes (P ⫽ 0.06) in animals of groups with SVN titers
higher than 1:8 at the time of challenge compared to the
control group (Fig. 2).
A titer of PRRSV-NA of 1:8 does not prevent local replication in lungs and dissemination of infection to other peripheral lymphoid tissues. To further characterize the protective
significance of the minimum level of PRRSV-NA necessary to
protect against viremia, systemic dissemination and shedding
to sentinels, we launched experiment 2. We used another two
groups of pigs passively transferred to attain a serum PRRSVneutralizing titer of 1:8 at the time of challenge, and the presence of virus in blood was monitored for 1 week in one group
and for 2 weeks in the second group. Table 1 shows that these
animals presented viremia when virus-neutralizing titers fall
below 1:8, thus confirming our previous observation indicating
a correlation between the titer of NA in blood and protection

against viremia after challenge. There is a clear correlation
between the presence of NA in the circulation at a given
threshold (1:8) and the blocking of the spread of PRRSV in
plasma. Above the threshold of 1:8 of NA in serum, cell-free
viremia (measured in this case in serum) is not detected.
In experiment 2, although no virus was detected in serum of
animals with a titer of 1:8 (Table 1), PRRSV was detected in
bronchial lymph node and lungs of all nonviremic animals
necropsied at day 7 p.i. (data not shown), which is consistent
with the prior results of experiment 1. Figure 3 shows the
infectious PRRSV load in different tissues in all of the animals
sacrificed at day 14 p.i. PRRSV has disseminated to the lymph
nodes and tonsils of these nonviremic animals. However, the
amount of virus was lower (P ⬍ 0.05) in animals with an SVN
titer of 1:8 at the time of challenge. The presence of viral RNA
in PBMC (buffy coat) measured at 7 days p.i. (Table 1) is

FIG. 3. Dissemination of PRRSV in PRRSV immunoglobulin-transferred pigs. Two-week-old pigs were transferred with serum to reach a titer
of 1:8 and challenged 1 day later with a dose of 105 TCID50/ml (experiment 2). At 14 days p.i., five animals were sacrificed, and tissues were
collected to determine the virus load in each tissue (105 TCID50/g of tissue). The amount of virus was lower (P ⬍ 0.05 [Student t test], 9 df) in
pools from animals with a titer of 1:8.
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Day 0

Viremia
at day
7 p.i.c

ID no.

VOL. 14, 2007

PROTECTION BY PRRSV-NEUTRALIZING ANTIBODIES IN PIGS

273

TABLE 2. Dissemination of PRRSV in tissues in pigs with a titer of 1:32 of NA in seruma
Viral load in tissues at day 14b

Titer at day:
Pig ID no.

26
27
28
29
32
33
37
38
34

0 (NA)

7 p.i.
(NA)

7 p.i.
(viremia)b

14 p.i.
(NA)

14 p.i.
(viremia)b

Lung

Lymph
node

Tonsils

Pool

1:32
1:32
1:32
1:32
1:16
1:16
⫺
⫺
⫺

1:16
1:16
1:16
1:16
1:8
1:16
⫺
⫺
⫺

⫺
⫺
⫺
⫺
⫺
⫺
105.6
105.5
105.0

1:8
1:8
1:8
1:8
1:4
1:8
⫺
⫺
⫺

–
⫺
⫺
⫺
⫺
⫺
104.3
104.0
104.3

⫺
⫺
⫺
⫺
104.6
103.0
ND
ND
ND

⫺
100.6
⫺
⫺
104.0
102.0
ND
ND
ND

⫺
102.6
⫺
⫺
104.0
102.6
ND
ND
ND

⫺
⫺
⫺
⫺
102.5
102.5
ND
ND
ND

consistent with a cell-associated pattern of viral spread by cells
circulating in blood. The systemic dissemination of the infection in these nonviremic animals explains the readily demonstrated transmission to sentinel pigs in experiments 2 and 3 as
described below.
Passive transfer of PRRSV-NA at a higher concentration
(SVN titer of 1:32) induces full protection, but only in some of
the young pigs. A new experiment (experiment 3) was aimed at
determining the minimum amount of NA needed to protect
against viral spread to organs, thus preventing transmission to
contacts. Six 15-day-old pigs were then transferred with our
immunoglobulin stock to attain a titer of 1:32 and challenged
with PRRSV (PRRSV IA 97-7895, 105 TCID50), and the presence of virus in blood and several organs was studied. Three
additional animals not treated with antibodies were used as
unprotected, challenged controls. In addition, the principal
and control animal groups were put in contact with two sets
each of two sentinel pigs (one sentinel pig colodged with principals from day 2 p.i. to day 9 p.i. and was then rotated to be
replaced by a second sentinel animal that was in contact with
the principal animals from days 9 to 14 p.i.) as previously
described for experiment 2. As shown in Table 2, no viremia
was detected in any of the animals exhibiting an SVN titer of
1:16 to 1:32 since the start of the experiment up to 14 days p.i.
At necropsy (14 days p.i.), three of the principals exhibited
viral replication in peripheral tissues, as evidenced by sizable
viral load in lungs, lymph nodes, and tonsils (Table 2). Interestingly, the remaining three nonviremic principals did not
exhibit any detectable viral load in peripheral tissues, thus
suggesting that sterilizing immunity may have been achieved in
these cases. Thus, the presence of more elevated concentrations of NA in blood may protect against infection, as well as
prevent the dissemination of the virus. As can be seen below,
the full protective effect in three of the six principal animals
determined that the transmission to contacts was significantly
delayed, although not prevented (see below).
Shedding and transmission of PRRSV occurs in the absence
of viremia. The definitive significance of the protective effect of
PRRSV-NA is given by the ability of passive transfer of NA to
block transmission of the infection to contact sentinel animals.
To determine whether the amount of circulating NA correlates
with blocking of shedding and transmission of virus, PRRSV-

free sentinel pigs were lodged during experiments 2 and 3 with
animals that had received NA and subsequently been challenged with PRRSV. At 9 days p.i. both sentinel animals
lodged with nonviremic animals having an SVN titer of 1:8
were scored as positively infected by viremia and seroconversion (Table 3); consequently, the second set of sentinel animals
maintained in contact with the same “donor” group between
days 9 and 14 p.i. were also scored as infected. Likewise, the
control group consistently transmitted the infection throughout the entire period of 14 days (Table 3). In contrast, despite
contact, the group that had received a higher dose of passive
NA (to titers of 1:16 to 1:32) (Table 2) remained uninfectious
for the first 9 days p.i. (Table 3), and only during the last 5 days
of contact did the transmission take place (Table 3). The overall results clearly indicate that the lack of viremia in the challenged (donor) animal does not correlate with the ability to
shed and transmit PRRSV. Likewise, the results show a significant delay in the transmission of infection when higher titer
of antibodies were transferred, which is in agreement with the
fact that only half (three of six) of the “donor” animals had
actually been infected (Table 2), thus reducing the overall load

TABLE 3. Shedding of virus from nonviremic pigs
to contact animalsa

SVN

1:8 (expt 2)
1:16–1:32 (expt 3)
Not protected/infection
controls

Viremia in
donors during
contact periodb

⫺
⫺
⫹

Transmission to
sentinel pigsc
2 to 9
days
p.i.

9 to 14
days
p.i.

⫹
⫺
⫹

⫹
⫹
⫹

a
Fifteen-day-old pigs were transferred with antibodies to attain a titer of 1:8
(experiment 2) or 1:16 to 1:32 (experiment 3). One day later the animals were
challenged with PRRSV. Two sentinel animals per group were lodged with the
challenged animals (“donors”) from days 2 to 9 after infection, removed for
isolation for 14 days, replaced with another two new sentinel pigs that were
lodged with the donor animals from days 9 to 14 p.i., and then kept in an isolation
room for 14 more days.
b
Virus in blood was determined at days 9 and 14 p.i.
c
The presence of antibodies by PRRSV-ELISA was determined at days 16
and 21.
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a
A group (n ⫽ 6) of 15-day-old piglets received NA to attain a titer of 1:32 before challenge with PRRSV (experiment 3). Three animals were used as controls
(non-serum transfer). At days 7 and 14 p.i., virus titers in serum were determined. At day 14 day p.i. the animals (except controls) were necropsied, and lung, lymph
node, tonsils, and a pool of lymph nodes were collected and prepared as described in Materials and Methods. –, undetectable viremia.
b
Values are TCID50s/ml of serum. ND, not done.
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of virus shed and consequently delaying the transmission to
uninfected contacts.
DISCUSSION
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Previously, we demonstrated that NA is a parameter of protection against PRRSV infection in pregnant sows (11). These
results prompted us to determine the minimal dose of NA that
will protect pigs from infection in an attempt to quantify the
significance of this parameter of protection. With this aim, we
performed a first experiment using a stock of NA administered
to 2-week-old pigs in different quantities to attain different
SVN titers in blood. The results of this experiment indicated
that animals with titers of 1:8 or more did not develop viremia,
whereas animals with a titer of 1:4 or less did develop viremia
(Fig. 1). This experiment confirms the importance of NA as a
parameter of protection against PRRSV and demonstrates
that there is a threshold of neutralizing antibody titer (seemingly 1:8) above which animals are protected from viremia
after challenge.
In addition, an important conclusion that results from experiment 1 is that immunoglobulin fractions containing NA are
effective in clearing viremia and protecting pigs. No evidence
of protection was exhibited by the group instilled with PRRSVspecific but non-neutralizing antibodies. This observation is
important since it confirms that the protective effect of the
passive transfer of immunoglobulins (i.e., the clearance of viremia) would be related to the neutralizing antibody fraction and
that the early non-neutralizing antibodies that determine the
seroconversion to PRRSV detectable by use of the commercial
ELISA kits are not responsible for protection. On the contrary,
the group of animals receiving non-neutralizing antibodies also
showed significantly higher temperatures during the length of
experiment 1 (7 days) and a tendency to develop interstitial
pneumonia that was detected upon necropsy (data not shown).
This would suggest a role for non-neutralizing antibodies in
inducing inflammation and enhancement of infection as has
been described previously (22). Alternatively, it is possible that
the exacerbating effect on disease symptoms and pathology
affecting the group treated with non-neutralizing PRRSV antibodies may have been caused by proinflammatory mediators
that are systemically abundant in acutely PRRSV-infected pigs
(17, 18). The PRRSV-specific non-neutralizing immunoglobulin solution, which was harvested from the sera of acutely
infected pigs, may have carried these molecules as well.
From the results of experiments 1, 2, and 3, a major conclusion that can be drawn is that the transfer of PRRSV-NA at a
moderate level may mitigate clinical symptoms but not necessarily clear infection in young weaned pigs. It was observed that
a reduced viral load in tissues and a clearance of the viremia
were observed in animals that had received NA at a titer of at
least 1:8. However, the presence of anti-PRRSV-NA in serum
at a titer of 1:8 interferes with the development of viremia but
does not prevent peripheral tissue seeding and transmission to
contact animals. Under the maximal concentration of NA attainable by passive transfer in our experimental system (1:32,
Table 2), an apparent sterilizing immunity was achieved in at
least three of six animals, which suggests that the full protective
effect may be related to a threshold of replicating virus to be
overcome by antibodies in young animals. The virus was de-

tected in the peripheral organs of the other animal exhibiting
a titer of 1:32 (although at a relatively lower viral load level).
Considering that the SVN assay provides a semiquantitative
measurement of neutralizing antibodies, it is possible that this
animal corresponds to a borderline level of protection. In contrast, the other two animals in which a titer of 1:32 was not
reached were not protected from infection dissemination. Such
a threshold could be higher in young pigs than in sows in which
sterilizing immunity was attained in individuals at lower concentrations of neutralizing antibody transfer (11). A possible
reason for the occurrence of this higher threshold of NA protection being required in young pigs may be based on the age
dependence of the permissiveness of swine macrophages to
PRRSV replication. It has been reported that the susceptibility
of the macrophages of young pigs is higher than the macrophages of adult swine (10). It is conceivable that the overall
infectious yield and load in young pigs infected with PRRSV is
higher than in adults, thus requiring higher concentrations of
NA to achieve protection in young pigs.
An apparent paradox was observed in our experiments: animals that had been treated with NA and had then achieved a
nonviremic status (based on the lack of detection of either
infectious PRRSV or RT-PCR signal in serum) not only presented dissemination of infection to and replication of PRRSV
in peripheral tissues but also were able to shed infectious
PRRSV and infect sentinel animals (Table 3). These results
indicate that pigs that are scored as “nonviremic” according to
the routine diagnostic paradigms in use (i.e., animals that do
not have free virus in blood, as detected in serum, which is the
sample commonly submitted to a diagnostic lab) still can excrete PRRSV in sufficient doses to infect other animals. Although the sera of our nonviremic animals contained no
PRRSV RNA, RT-PCR conducted in buffy coat cells of the
same animals indicated the presence of PRRSV in PBMC
(Table 1). This suggests that, in addition to cell-free virus in
blood, the PRRSV pathogenesis and dissemination is based on
the spread of infection and persistence through an intracellular
route. Our observation is in agreement with previous reports
indicating the presence of minute amounts of PRRSV in buffy
coat cells of infected animals (3, 16) and gives support to
previous work of other laboratory suggesting the possible occurrence of transmission to contact controls, from persistently
infected sows, in the absence of detectable viremia in the index
sows (4). Our experiments show a high viral load in the tonsils
in nonviremic pigs transferred with serum to reach an SVN
titer of 1:8 (Fig. 3). Tonsils are known to be as a site of
persistent infection (2, 3); thus, this tissue could play a major
role in the transmission to sentinels (Table 3). The cell-to-cell
dissemination of PRRSV and spread through mononuclear
cells might also help to explain the differences in pathogenesis
and susceptibility to passive antibody protection that we observed between adult sows and young pigs. It is likely that in
our previous report of passive protection in sows (11), the level
of antibodies injected in the sows was sufficient to completely
preclude the transplacental infection, just by completely clearing the circulation of cell-free PRRSV. Our results suggest that
the blood mononuclear cells can also disseminate the infection.
Therefore, a complete, more accurate in vivo assessment of the
PRRSV infection status of a pig by RT-PCR can only be
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obtained from an analysis of buffy coat cells in addition to
serum.
In conclusion, these results identify certain threshold of
SVN titer (ⱖ1:8) at which the dissemination of PRRSV in the
serum of a young pig would be blocked, as well as a higher
threshold (ⱖ1:32) that could imply complete protection of the
animal from PRRSV infection. Finally, the results also indicate
that the absence of PRRSV in the sera of young pigs does not
necessarily imply complete freedom from PRRSV infection.
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